To outline FDA regulatory decisions for various therapies and products scheduled for August 2026.
Approach:
Infectious Disease: Moderna's mRNA-1010 influenza vaccine has an August 5, 2026, PDUFA target action date, supported by phase 3 data.
HIV Treatment: Gilead's bictegravir/lenacapavir application for HIV has an August 27, 2026, PDUFA date, based on phase 3 ARTISTRY trials.
Neurology: Lantheus' MK-6240 for Alzheimer imaging has an August 13, 2026, PDUFA date, supported by pivotal phase 3 trials.
Duchenne Muscular Dystrophy: Capricor's deramiocel application has an August 22, 2026, PDUFA date, supported by phase 2 and 3 trial data.
Oncology: Bristol Myers Squibb's iberdomide for multiple myeloma has an August 17, 2026, PDUFA date, based on phase 3 trial analysis.
HER2-positive Cancer Treatment: Jazz Pharmaceuticals' Ziihera application has an August 25, 2026, PDUFA date, supported by phase 3 HERIZON-GEA-01 trial data.
Pulmonary Disease: Savara's MOLBREEVI for autoimmune pulmonary alveolar proteinosis has an August 22, 2026, PDUFA date.
Pediatrics: Ultragenyx's DTX401 for glycogen storage disease type Ia has an August 23, 2026, PDUFA date, supported by clinical data.
Key Findings:
Moderna's mRNA-1010 vaccine received unanimous support from the FDA advisory committee.
Gilead's bictegravir/lenacapavir application is based on phase 3 data from the ARTISTRY trials.
Lantheus' MK-6240 met diagnostic sensitivity and specificity endpoints in pivotal trials.
Capricor's deramiocel application is supported by findings from the phase 2 HOPE-2 trial and phase 3 HOPE-3 trial.
Bristol Myers Squibb's iberdomide received Breakthrough Therapy designation.
Jazz Pharmaceuticals' Ziihera application is based on findings from the phase 3 HERIZON-GEA-01 trial.
Savara's MOLBREEVI application is under review without an advisory committee meeting planned.
Ultragenyx's DTX401 application is supported by clinical data from a substantial patient cohort.
Interpretation:
The FDA is set to review multiple significant therapies across various medical fields in August 2026.
Limitations:
The article does not provide detailed clinical outcomes or statistical significance for all trials mentioned.
Future applications have unspecified PDUFA dates, limiting immediate context.
Conclusion:
The upcoming FDA decisions could impact treatment options across several medical conditions.
